Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib vs Imatinib in newly diagnosed CML
NCT00481247Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2007
- Primary completion
- Dec 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 27
01
Overview
A Phase 3 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Sep 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00481247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481247.